US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Park Hotels & Resorts Inc.

10.00

+0.01000.10%

Post-market: 10.040.0400+0.40%17:59 EDT

Volume:3.48M

Turnover:34.70M

Market Cap:2.02B

PE:9.90

High:10.03

Open:9.98

Low:9.82

Close:9.99

Loading ...

Overview Company News Filings

Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

COCP: Phase 2a Trial of CC-42344 Extended…

Zacks Small Cap Research

FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia

Final Study Completed for Cingulate’s Lead Asset CTx-1301

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

Park Hotels & Resorts Is Maintained at Buy by Jefferies

Japan Approves SIGA Technologies Antiviral As First For Smallpox, Mpox

Wedbush Trims Price Target on Park Hotels & Resorts to $15 From $16, Keeps Neutral Rating

MT Newswires Live

TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Press Release: Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Assembly Biosciences announces interim PK, efficacy from Phase 1b study

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

Press Release: Park Hotels & Resorts Inc. Announces Fourth Quarter and Full Year 2024 Earnings Conference Call on February 20, 2025

Why RAPT Therapeutics Stock Gained Over 100% On Monday?

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PK/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PK","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PK\",,,,,undefined,":{"symbol":"PK","market":"US","secType":"STK","nameCN":"Park Hotels & Resorts Inc.","latestPrice":10,"timestamp":1745611200000,"preClose":9.99,"halted":0,"volume":3479513,"hourTrading":{"tag":"盘后","latestPrice":10.04,"preClose":10,"latestTime":"17:59 EDT","volume":137436,"amount":1374381.11,"timestamp":1745618344339},"delay":0,"floatShares":197724425,"shares":201864175,"eps":1.01,"marketStatus":"Market Closed","change":0.01,"latestTime":"04-25 16:00:00 EDT","open":9.98,"high":10.0253,"low":9.815,"amount":34696301.392261,"amplitude":0.021051,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.01,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":9.99,"dividendRate":0.14,"preHourTrading":{"tag":"盘前","latestPrice":10.18,"preClose":9.99,"latestTime":"09:25 EDT","volume":291,"amount":2960.915397,"timestamp":1745587526246},"postHourTrading":{"tag":"盘后","latestPrice":10.04,"preClose":10,"latestTime":"17:59 EDT","volume":137436,"amount":1374381.11,"timestamp":1745618344339},"volumeRatio":0.8356835002679648,"impliedVol":0.5641,"impliedVolPercentile":0.812},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PK\",,,,,undefined,":{"symbol":"PK","floatShares":197724425,"roa":"2.35%","roe":"6.14%","lyrEps":1.019323,"volumeRatio":0.8356835002679648,"shares":201864175,"dividePrice":1.4,"high":10.0253,"amplitude":0.021051,"preClose":9.99,"low":9.815,"week52Low":8.27,"pbRate":"0.55","psRate":"0.77","week52High":16.78,"institutionHeld":0,"latestPrice":10,"eps":1.01,"divideRate":0.14,"volume":3479513,"delay":0,"ttmEps":1.01,"open":9.98,"prevYearClose":14.07,"prevWeekClose":9.83,"prevMonthClose":10.68,"prevQuarterClose":10.68,"fiveDayClose":9.83,"twentyDayClose":11.15,"sixtyDayClose":13.35,"earningDate":1746374400000,"earningTime":"盘前"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PK\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2502011140","title":"Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings","url":"https://stock-news.laohu8.com/highlight/detail?id=2502011140","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502011140?lang=en_us&edition=fundamental","pubTime":"2025-01-09 21:00","pubTimestamp":1736427600,"startTime":"0","endTime":"0","summary":"Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer’s Disease supports continued development of sabirnetug (ACU193) for treatment of early Alzheimer’s disease (AD) Sabirnetug dem","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/09/3007016/0/en/Acumen-Pharmaceuticals-Announces-Journal-of-Prevention-of-Alzheimer-s-Disease-Publication-of-the-Company-s-Phase-1-INTERCEPT-AD-Study-Including-Target-Engagement-Dosing-Regimen-and.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABOS","PK","BK4139","BK4539","BK4181","BK4218","ARIA"],"gpt_icon":0},{"id":"2502015616","title":"Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2502015616","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502015616?lang=en_us&edition=fundamental","pubTime":"2025-01-09 20:00","pubTimestamp":1736424000,"startTime":"0","endTime":"0","summary":"In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted neuroanatomica","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/09/3006949/0/en/Rapport-Therapeutics-Announces-New-Phase-1-Data-Further-Supporting-RAP-219-s-Transformative-Potential-for-CNS-Disorders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4129","PK","ECG","BK4135","BK4218","LENZ","CNS","BK4181","BK4007","PET","BK4192","BK4139"],"gpt_icon":0},{"id":"2502709098","title":"COCP: Phase 2a Trial of CC-42344 Extended…","url":"https://stock-news.laohu8.com/highlight/detail?id=2502709098","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502709098?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:05","pubTimestamp":1736341500,"startTime":"0","endTime":"0","summary":"On December 31, 2024, Cocrystal Pharma, Inc.  announced that the Phase 2a clinical trial of its oral PB2 inhibitor, CC-42344, will be extended due to unexpectedly low infection rates among trial participants that were challenged with a H3N2 influenza strain. The Phase 2a trial initiated in December 2023 and completed enrollment in May 2024 with 78 total participants. It is a single center study being conducted in the U.K. designed to test the safety, tolerability, pharmacokinetics , antiviral activity, and clinical measurements of CC-42344.There are no approved therapies for norovirus infection, which is the most common cause of acute gastroenteritis. According to the Centers for Disease Control , there are an estimated 685 million cases and 200,000 deaths caused by norovirus infection each year worldwide. In the U.S., norovirus","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cocp-phase-2a-trial-cc-130500351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","BK4218","BK4098","CC","CDC","COCP","PK","BK4007"],"gpt_icon":0},{"id":"2501872302","title":"FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2501872302","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501872302?lang=en_us&edition=fundamental","pubTime":"2025-01-08 20:00","pubTimestamp":1736337600,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Jan.  08, 2025  (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare dise","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/08/3006111/31990/en/FDA-Accepts-Agios-Supplemental-New-Drug-Application-for-PYRUKYND-mitapivat-in-Adult-Patients-with-Non-Transfusion-Dependent-and-Transfusion-Dependent-Alpha-or-Beta-Thalassemia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","PK","BK4218"],"gpt_icon":0},{"id":"2501203113","title":"Final Study Completed for Cingulate’s Lead Asset CTx-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2501203113","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501203113?lang=en_us&edition=fundamental","pubTime":"2025-01-07 20:30","pubTimestamp":1736253000,"startTime":"0","endTime":"0","summary":"No Serious Adverse Events ReportedSubmission of New Drug Application Targeted for Mid 2025. KANSAS CITY, Kan., Jan. 07, 2025  -- Cingulate Inc., a biopharmaceutical company utilizing its proprietary Precision Timed Release  drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has completed its final FDA-required study, which is a food effect study, for CTx-1301  for the treatment of Attention Deficit Hyperactivity Disorder .The primary PK endpoints were maximum concentration  during the first 28 hours after dosing, and the total amount of the active pharmaceutical ingredient , dexmethylphenidate, in the blood  from dosing to the time of the last measured concentration  and from dosing taken to the limit as the end time becomes arbitrarily large . Overall, the effect of food on the PK of orally administered long-acting stimulants is generally minimal: following a high-fat meal, there is potential for the ra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/final-study-completed-cingulate-lead-123000121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADHD","BK4139","BK4218","CINGW","BK4181","BK4503","BK4535","BK4007","BK4023","CING","ABVC","API","ADME","PK","BK4551"],"gpt_icon":0},{"id":"2501585882","title":"Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2501585882","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501585882?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:30","pubTimestamp":1736170200,"startTime":"0","endTime":"0","summary":"Acurx has now received positive written responses from the EMA  under its Scientific Advice Procedure that the clinical, non-clinical and CMC  information package submitted supports advancement of the ibezapolstat Phase 3 program. The responses also included guidance on ibezapolstat's regulatory pathway for a Marketing Authorization Application for ibezapolstat in CDI. With mutually consistent feedback from both EMA and FDA, Acurx is well positioned to commence our international Phase 3 registration program. Acurx is also preparing to request regulatory guidance to initiate clinical trials in Japan, Canada and the United Kingdom. Ibezapolstat has previously been granted FDA QIDP and Fast-Track Designation from FDA and Acurx has received SME  designation by the EMA to benefit from fee incentives and other support from the EMA for EU Marketing Authorization. Acurx previously announced it had a successful End of Phase 2 Meeting achieving agreement with FDA on non-clinical and clinical Pha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/acurx-receives-positive-regulatory-guidance-133000707.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acurx-receives-positive-regulatory-guidance-133000707.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACXP","PK","BK4539","VRE","BK4181","BK4218","BK4563","GAIN","IDSA","BK4194","ECC","BK4135","BK4139"],"gpt_icon":0},{"id":"2500197830","title":"Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2500197830","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500197830?lang=en_us&edition=fundamental","pubTime":"2025-01-03 20:00","pubTimestamp":1735905600,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Jan.  03, 2025  (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/03/3003947/31990/en/Agios-to-Present-at-the-43rd-Annual-J-P-Morgan-Healthcare-Conference-on-January-15-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023251221.USD","LU0795875086.SGD","LU1074936037.SGD","LU2089284900.SGD","HCSG","LU1732800096.USD","LU0158827948.USD","LU0006306889.USD","BK4581","BK4137","LU0795875169.SGD","BK4181","LU1732799900.SGD","IE00BZ1G4Q59.USD","LU2357305700.SGD","LU0971096721.USD","BK4516","LU0225283273.USD","LU2111349929.HKD","BK4534","LU0314104364.USD","PK","LU1668664300.SGD","LU1548497426.USD","LU1720051017.SGD","BK4218","LU0106831901.USD","LU1989772840.SGD","BK4504","LU0912757837.SGD","LU2347655156.SGD","LU1989772923.USD","LU2089283258.USD","LU1363072403.SGD","LU0320765646.SGD","BK4588","LU1720051108.HKD","LU1162221912.USD","BK4127","LU2271345857.HKD","LU0098860793.USD","LU0106261372.USD","LU2028103732.USD","LU0158827781.USD","BK4585","LU0267386448.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2500971599","title":"Park Hotels & Resorts Is Maintained at Buy by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2500971599","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500971599?lang=en_us&edition=fundamental","pubTime":"2025-01-03 00:48","pubTimestamp":1735836480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PK/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 02, 2025 11:48 ET (16:48 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK"],"gpt_icon":0},{"id":"2500971574","title":"Japan Approves SIGA Technologies Antiviral As First For Smallpox, Mpox","url":"https://stock-news.laohu8.com/highlight/detail?id=2500971574","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500971574?lang=en_us&edition=fundamental","pubTime":"2025-01-02 23:10","pubTimestamp":1735830622,"startTime":"0","endTime":"0","summary":"On Thursday,the Japan Ministry of Health, Labour and Welfare approved SIGA Technologies  antiviral treatment TEPOXX  for smallpox, mpox, cowpox, as well as complications following smallpox vaccination in adults and pediatric patients weighing at least 13 kg.TEPOXX is the first antiviral therapy for orthopoxviruses approved by Japan's drug regulator in collaboration with the Ministry of Health, Labour, and Welfare.In partnership with Japan Biotechno Pharma, SIGA's exclusive distributor in Japan, SIGA has delivered an order of TEPOXX to help build Japan's strategic national stockpile.Also Read: In NIH-Cosponsored Mpox Virus Study In Congo, SIGA Technologies' Antiviral Tecovirimat Did Not Improve Lesion Resolution, Stock Tanks. The Japanese approval is based on data from 15 clinical trials of oral TEPOXX in over 800 healthy volunteers, including a pivotal repeat-dose phase 1 pharmacokinetics  trial involving 20 healthy volunteers conducted in Japan.This article Japan Approves SIGA Technol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/japan-approves-siga-technologies-antiviral-151022382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SIGA","BK4007","BK4583","PK","BK4181","BK4218"],"gpt_icon":0},{"id":"2500233779","title":"Wedbush Trims Price Target on Park Hotels & Resorts to $15 From $16, Keeps Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2500233779","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500233779?lang=en_us&edition=fundamental","pubTime":"2025-01-02 20:42","pubTimestamp":1735821725,"startTime":"0","endTime":"0","summary":"Park Hotels & Resorts (PK) has an average rating of overweight and mean price target of $17.18, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PK"],"gpt_icon":0},{"id":"2500923820","title":"TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses","url":"https://stock-news.laohu8.com/highlight/detail?id=2500923820","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500923820?lang=en_us&edition=fundamental","pubTime":"2025-01-02 20:30","pubTimestamp":1735821000,"startTime":"0","endTime":"0","summary":"Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapanBiotechno Pharma Co., Ltd. engaged as exclusive distribut","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/02/3003478/9738/en/TEPOXX-tecovirimat-Approved-in-Japan-for-the-Treatment-of-Orthopoxviruses.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","PK","BK4218"],"gpt_icon":0},{"id":"2495692620","title":"Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344","url":"https://stock-news.laohu8.com/highlight/detail?id=2495692620","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495692620?lang=en_us&edition=fundamental","pubTime":"2024-12-31 21:00","pubTimestamp":1735650000,"startTime":"0","endTime":"0","summary":"Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related drug discontinuationsEnrollment to be extended due to low influenza infection among challe","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/31/3003109/0/en/Cocrystal-Pharma-to-Extend-Phase-2a-Influenza-Challenge-Study-with-Oral-PB2-inhibitor-CC-42344.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","BK4218","BK4098","CC","PK"],"gpt_icon":0},{"id":"2495854117","title":"Press Release: Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2495854117","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495854117?lang=en_us&edition=fundamental","pubTime":"2024-12-30 21:00","pubTimestamp":1735563600,"startTime":"0","endTime":"0","summary":"Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval. Initial tranche of $20 Million extends cash runway into 1H26, subsequent tranche of up to $52.6 Million will provide for runway 3+ years enabling the company to reach both near-term and long-term value inflecting readouts. \"We are appreciative of the support from new and existing institutional investors including Perceptive Advisors, OrbiMed, Alyeska, Torrey Pines and Ikarian Capital. This financing by high quality investors is transformative for Traws and highlights the meaningful potential for Tivoxavir Marboxil,\" said Iain D. Dukes, MA, DPhil, Executive Chairman of Traws Pharma and Venture Partner of OrbiMed.Traws Pharma will host an update call on Tivoxavir Marboxil during the first quarter of 2025 with additional details forthcoming.This announcement is neither an offer to sell, nor a solicitation of an ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4007","TRAW","ISBC","BK4218","CEN","BK4137","HCSG","PK","BK4181","CDC"],"gpt_icon":1},{"id":"2494850522","title":"Assembly Biosciences announces interim PK, efficacy from Phase 1b study","url":"https://stock-news.laohu8.com/highlight/detail?id=2494850522","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494850522?lang=en_us&edition=fundamental","pubTime":"2024-12-26 21:05","pubTimestamp":1735218311,"startTime":"0","endTime":"0","summary":"Assembly Biosciences (ASMB) announced interim safety, pharmacokinetic, PK, and efficacy results from participants with chronic hepatitis B virus, H...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/assembly-biosciences-announces-interim-pk-efficacy-from-phase-1b-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/assembly-biosciences-announces-interim-pk-efficacy-from-phase-1b-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PK","BK4181","BK4218","BK4139","ASMB"],"gpt_icon":0},{"id":"2494585774","title":"Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B","url":"https://stock-news.laohu8.com/highlight/detail?id=2494585774","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494585774?lang=en_us&edition=fundamental","pubTime":"2024-12-26 21:00","pubTimestamp":1735218000,"startTime":"0","endTime":"0","summary":"– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed –  – In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity w","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/26/3001938/16259/en/Assembly-Biosciences-Reports-Interim-Phase-1b-Results-from-Clinical-Trial-Evaluating-Next-Generation-Capsid-Assembly-Modulator-Candidate-ABI-4334-in-Chronic-Hepatitis-B.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASMB","BK4139","BK4181","BK4599","LU1878469433.USD","BK4588","HDV","PK","BK4585","BK4218","ALT"],"gpt_icon":0},{"id":"2493194716","title":"Press Release: Park Hotels & Resorts Inc. Announces Fourth Quarter and Full Year 2024 Earnings Conference Call on February 20, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2493194716","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493194716?lang=en_us&edition=fundamental","pubTime":"2024-12-24 05:49","pubTimestamp":1734990540,"startTime":"0","endTime":"0","summary":"Park Hotels & Resorts Inc. Announces Fourth Quarter and Full Year 2024 Earnings Conference Call on February 20, 2025. Park Hotels & Resorts Inc.   today announced that it plans to report financial results for the fourth quarter and full year 2024 after the stock market closes on Wednesday, February 19, 2025. Park will hold a conference call on Thursday, February 20, 2025, at 11:00 a.m. Eastern Time  to discuss its earnings results and outlook for 2025.The conference call will be accessible by telephone and through the internet. Interested individuals are invited to participate by following these steps:. Please dial  451-6152, or  389-0879 for international participants, and request Park Hotels & Resorts' Fourth Quarter and Full Year 2024 Earnings Conference Call. It is recommended that participants dial 10 minutes ahead of the scheduled start time.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK"],"gpt_icon":0},{"id":"2493291796","title":"Why RAPT Therapeutics Stock Gained Over 100% On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2493291796","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493291796?lang=en_us&edition=fundamental","pubTime":"2024-12-24 02:00","pubTimestamp":1734976820,"startTime":"0","endTime":"0","summary":"RAPT Therapeutics, Inc.  shares are trading higher after the company disclosed a partnership with Shanghai Jemincare Pharmaceutical.The collaboration is for an exclusive license agreement to develop and commercialize RPT904, a novel anti-IgE monoclonal antibody worldwide, excluding mainland China, Hong Kong, Macau, and Taiwan.RPT904 is designed to provide a potential alternative to omalizumab , addressing allergic conditions such as asthma and chronic spontaneous urticaria .As per the deal, Jemincare will receive a $35 million upfront payment, up to $672.5 million in regulatory and commercial milestone payments, and royalties on sales outside the Jemincare Territory.RAPT plans to focus on developing RPT904 for food allergies, while Jemincare is conducting Phase 2 trials in China for asthma and CSU.Jemincare has completed a Phase 1 study of JYB1904 in 56 healthy volunteers in China, evaluating safety, pharmacokinetics , and pharmacodynamics .Jemincare is now running two Phase 2 trials i","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/J72qDcOA01RWdlAMKLIjzQ--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/2067a370a39e49e69e5e7563ac2d3598","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/J72qDcOA01RWdlAMKLIjzQ--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/2067a370a39e49e69e5e7563ac2d3598"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-rapt-therapeutics-stock-gained-180020897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","BK4139","PK","LU1169590202.USD","PD","RAPT","BK4218","BK4023","LU1169589451.USD"],"gpt_icon":0},{"id":"2493751469","title":"Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu","url":"https://stock-news.laohu8.com/highlight/detail?id=2493751469","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493751469?lang=en_us&edition=fundamental","pubTime":"2024-12-23 20:00","pubTimestamp":1734955200,"startTime":"0","endTime":"0","summary":"Investigational agent in development for treatment or prevention of H5N1 Bird Flu. Potent inhibition of drug-resistant and bird flu viruses in vitro. In vivo study in mice, with H5N1 isolated from an infected dairy worker, showed potent protection and suppression of virus replication in lungs. Traws Pharma is expanding its influenza program to address the potential threat of bird flu. \"In laboratory testing, tivoxavir marboxil inhibited multiple isolates of highly pathogenic avian influenza H5N1. We evaluated the effects of drug treatment in mice exposed to human H5N1, where the virus was isolated from a dairy worker exposed to infected cattle,\" said C. David Pauza, PhD, Chief Science Officer for Traws Pharma. \"Oral treatment with tivoxavir marboxil after the virus infection resulted in complete survival and lung virus levels below the limit of quantitation1. This result is highly encouraging for future clinical development of tivoxavir marboxil for treating human H5N1 influenza.\". No ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YVNx2oT9dYISFKmaBZL4mA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/fa5b4fbc1407c77b5c22d9507acdc357","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YVNx2oT9dYISFKmaBZL4mA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/fa5b4fbc1407c77b5c22d9507acdc357"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/traws-pharma-announces-progress-developing-120000871.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/traws-pharma-announces-progress-developing-120000871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","CDC","BK4007","CEN","LU2065732104.USD","PK","BK4181","BK4218","PRGS","TRAW"],"gpt_icon":0},{"id":"2492175744","title":"InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904","url":"https://stock-news.laohu8.com/highlight/detail?id=2492175744","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492175744?lang=en_us&edition=fundamental","pubTime":"2024-12-20 20:30","pubTimestamp":1734697800,"startTime":"0","endTime":"0","summary":"JENA,Germany, Dec.  20, 2024  (GLOBE NEWSWIRE) -- InflaRxN.V.(Nasdaq:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/20/3000513/0/en/InflaRx-Announces-First-Patient-Dosed-in-Phase-2a-Study-for-Oral-C5aR-Inhibitor-INF904.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","USA","BK4023","QD","PK","BK4181","BK4503","PRO","BK4563","BK4166"],"gpt_icon":0},{"id":"2492312729","title":"Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005","url":"https://stock-news.laohu8.com/highlight/detail?id=2492312729","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492312729?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:00","pubTimestamp":1734613200,"startTime":"0","endTime":"0","summary":"– A-005 was well tolerated and demonstrated ability to cross blood-brain barrier – – Maximal TYK2 inhibition achieved with favorable pharmacokinetic profile in CNS and periphery – – Data support advan","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/19/2999795/0/en/Alumis-Announces-Positive-Phase-1-Data-for-CNS-Penetrant-TYK2-Inhibitor-A-005.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1548497426.USD","LU2089284900.SGD","LU1169590202.USD","LU0267386448.USD","LU1169589451.USD","LU1668664300.SGD","LU2089283258.USD","LU0912757837.SGD","ALMS","LU0098860793.USD","LU1732800096.USD","LU1162221912.USD","LU0971096721.USD","LU0106831901.USD","LU1732799900.SGD","BK4127","LU1363072403.SGD","LU0314104364.USD","LU0320765646.SGD","BK4023","PK","LU2028103732.USD","IE00BKVL7J92.USD","LU0225283273.USD","BK4007","BK4504","LU2023251221.USD","LU2111349929.HKD","LU1989772923.USD","LU0158827781.USD","PD","LU1989772840.SGD","BK4516","LU2271345857.HKD","BK4534","IE00BZ1G4Q59.USD","CNS","LU0106261372.USD","BK4218","LU0158827948.USD","LU0795875169.SGD","LU1720051108.HKD","LU1074936037.SGD","LU2357305700.SGD","BK4181","BK4581","BK4585","BK4588","LU0795875086.SGD","CSF"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PK\",params:#limit:5,,,undefined,":[{"date":"2025-05-05","symbol":"PK","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":0.39,"defaultRemindTime":1746432000000,"name":null,"time":"Pre-Market","dateTimestamp":1746417600000,"actualEps":null},{"date":"2025-03-31","symbol":"PK","amount":0.25,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-31","defaultRemindTime":1743427800000,"name":"Park Hotels & Resorts Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-15","payableDate":"2025-03-31","currency":"USD","dateTimestamp":1743393600000,"payDate":"2025-04-15"},{"date":"2025-02-19","symbol":"PK","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":0.37,"defaultRemindTime":1739998800000,"name":null,"time":"Post Market","dateTimestamp":1739941200000,"actualEps":null},{"date":"2024-12-31","symbol":"PK","amount":0.65,"announcedDate":"2024-11-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-31","defaultRemindTime":1735655400000,"name":"Park Hotels & Resorts Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-15","payableDate":"2024-12-31","currency":"USD","dateTimestamp":1735621200000,"payDate":"2025-01-15"},{"date":"2024-10-29","symbol":"PK","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/09","expectedEps":0.47,"defaultRemindTime":1730232000000,"name":null,"time":"Post Market","dateTimestamp":1730174400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PK\",market:\"US\",,,undefined,":[{"executeDate":"2017-03-29","recordDate":"2017-03-31","paymentDate":"2017-04-17","value":0.43,"currency":"USD"},{"executeDate":"2017-06-28","recordDate":"2017-06-30","paymentDate":"2017-07-17","value":0.43,"currency":"USD"},{"executeDate":"2017-09-28","recordDate":"2017-09-29","paymentDate":"2017-10-16","value":0.43,"currency":"USD"},{"executeDate":"2017-12-28","recordDate":"2017-12-29","paymentDate":"2018-01-16","value":0.55,"currency":"USD"},{"executeDate":"2018-03-28","recordDate":"2018-03-30","paymentDate":"2018-04-16","value":0.43,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PK\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.25,"hold":0.625,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.25,"analysts":16,"updateTime":1744257600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PK\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PK","date":"2025-04-25","current":9.512373,"percent":0.692687,"low":-68.24471,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"high":55.399897,"avg":-2.797796,"sd":27.198522,"marketCap":2016623108},"quantilePoints":[{"date":"2020-05-01","current":6.781686,"twenty":11.855583,"median":14.661134,"eighty":31.814372,"marketCap":2075195859},{"date":"2020-05-08","current":6.844479,"twenty":11.80177,"median":14.646936,"eighty":31.785807,"marketCap":2094410636},{"date":"2020-05-15","current":-3.602916,"twenty":11.684678,"median":14.629627,"eighty":31.749191,"marketCap":1722193974},{"date":"2020-05-22","current":-4.628096,"twenty":11.308585,"median":14.609077,"eighty":31.647673,"marketCap":2212230016},{"date":"2020-05-29","current":-4.844961,"twenty":11.239782,"median":14.592668,"eighty":31.498937,"marketCap":2315891487},{"date":"2020-06-05","current":-6.446805,"twenty":11.167874,"median":14.571217,"eighty":31.464863,"marketCap":3081572803},{"date":"2020-06-12","current":-5.712421,"twenty":11.131908,"median":14.542822,"eighty":31.43819,"marketCap":2730537369},{"date":"2020-06-19","current":-5.278691,"twenty":11.055905,"median":14.514879,"eighty":31.414917,"marketCap":2523214428},{"date":"2020-06-26","current":-4.682313,"twenty":10.886453,"median":14.495498,"eighty":31.375334,"marketCap":2238145384},{"date":"2020-07-02","current":-4.746386,"twenty":10.800505,"median":14.4813,"eighty":31.352562,"marketCap":2268772637},{"date":"2020-07-10","current":-4.756244,"twenty":10.682725,"median":14.429243,"eighty":31.344509,"marketCap":2273484522},{"date":"2020-07-17","current":-4.514735,"twenty":7.464564,"median":14.377186,"eighty":31.340758,"marketCap":2158043339},{"date":"2020-07-24","current":-4.204224,"twenty":6.899423,"median":14.324128,"eighty":31.317149,"marketCap":2009618961},{"date":"2020-07-31","current":-4.076076,"twenty":6.656099,"median":14.175607,"eighty":31.295818,"marketCap":1948364455},{"date":"2020-08-07","current":-2.566048,"twenty":6.428473,"median":14.137595,"eighty":31.259301,"marketCap":2101593620},{"date":"2020-08-14","current":-2.721392,"twenty":6.26364,"median":14.089266,"eighty":31.247128,"marketCap":2228820140},{"date":"2020-08-21","current":-2.525774,"twenty":6.153752,"median":14.006744,"eighty":31.247128,"marketCap":2068608967},{"date":"2020-08-28","current":-2.870982,"twenty":5.863333,"median":13.870814,"eighty":31.210909,"marketCap":2351334566},{"date":"2020-09-04","current":-3.046463,"twenty":5.667103,"median":13.801033,"eighty":31.128278,"marketCap":2495053412},{"date":"2020-09-11","current":-2.902626,"twenty":5.384533,"median":13.774657,"eighty":31.118835,"marketCap":2377251079},{"date":"2020-09-18","current":-3.095368,"twenty":4.792705,"median":13.714879,"eighty":31.059812,"marketCap":2535106206},{"date":"2020-09-25","current":-2.819201,"twenty":2.477694,"median":13.678818,"eighty":30.998429,"marketCap":2308925726},{"date":"2020-10-02","current":-3.046463,"twenty":2.452731,"median":13.647472,"eighty":30.967738,"marketCap":2495053412},{"date":"2020-10-09","current":-3.103998,"twenty":2.419945,"median":13.625211,"eighty":30.925242,"marketCap":2542174346},{"date":"2020-10-16","current":-2.865229,"twenty":2.407631,"median":13.604071,"eighty":30.830806,"marketCap":2346622473},{"date":"2020-10-23","current":-3.106875,"twenty":2.39881,"median":13.60157,"eighty":30.809558,"marketCap":2544530392},{"date":"2020-10-30","current":-2.856599,"twenty":2.384831,"median":13.570144,"eighty":30.743453,"marketCap":2339554333},{"date":"2020-11-06","current":-2.206192,"twenty":2.293797,"median":13.511461,"eighty":30.717484,"marketCap":2426811706},{"date":"2020-11-13","current":-3.043689,"twenty":2.260846,"median":13.488575,"eighty":30.70568,"marketCap":3348057703},{"date":"2020-11-20","current":-3.221469,"twenty":2.22504,"median":13.471041,"eighty":30.674988,"marketCap":3543616316},{"date":"2020-11-27","current":-3.581314,"twenty":2.209754,"median":13.450169,"eighty":30.667905,"marketCap":3939445798},{"date":"2020-12-04","current":-3.885469,"twenty":2.206595,"median":13.437336,"eighty":30.660823,"marketCap":4274015956},{"date":"2020-12-11","current":-3.77623,"twenty":2.197164,"median":13.4098,"eighty":30.634853,"marketCap":4153853434},{"date":"2020-12-18","current":-3.649856,"twenty":2.188516,"median":13.398907,"eighty":30.606523,"marketCap":4014841890},{"date":"2020-12-24","current":-3.681985,"twenty":2.181468,"median":13.390367,"eighty":30.587635,"marketCap":4050183808},{"date":"2020-12-31","current":-3.673418,"twenty":2.165633,"median":13.373288,"eighty":30.559305,"marketCap":4040759297},{"date":"2021-01-08","current":-3.726966,"twenty":2.127386,"median":13.357167,"eighty":30.487456,"marketCap":4099662493},{"date":"2021-01-15","current":-3.711972,"twenty":2.090996,"median":13.34366,"eighty":30.406499,"marketCap":4083169598},{"date":"2021-01-22","current":-3.889753,"twenty":2.071846,"median":13.334859,"eighty":30.325661,"marketCap":4278728211},{"date":"2021-01-29","current":-3.572747,"twenty":2.068781,"median":13.320798,"eighty":30.089882,"marketCap":3930021287},{"date":"2021-02-05","current":-3.887611,"twenty":2.05882,"median":13.314589,"eighty":29.899013,"marketCap":4276372084},{"date":"2021-02-12","current":-4.215327,"twenty":2.034301,"median":13.288201,"eighty":29.854103,"marketCap":4636859648},{"date":"2021-02-19","current":-4.444514,"twenty":2.013845,"median":13.280132,"eighty":29.737337,"marketCap":4888965330},{"date":"2021-02-26","current":-3.563311,"twenty":-2.231897,"median":13.271323,"eighty":29.699163,"marketCap":5131167540},{"date":"2021-03-05","current":-3.448497,"twenty":-2.455006,"median":13.256856,"eighty":29.625061,"marketCap":4965836198},{"date":"2021-03-12","current":-3.740659,"twenty":-2.561446,"median":13.245191,"eighty":29.508294,"marketCap":5386549593},{"date":"2021-03-19","current":-3.755425,"twenty":-2.654652,"median":13.226158,"eighty":29.474611,"marketCap":5407812650},{"date":"2021-03-26","current":-3.589648,"twenty":-2.723118,"median":13.200933,"eighty":29.409492,"marketCap":5169093647},{"date":"2021-04-01","current":-3.581442,"twenty":-2.747858,"median":13.188305,"eighty":29.387036,"marketCap":5157275875},{"date":"2021-04-09","current":-3.522353,"twenty":-2.785256,"median":13.150762,"eighty":29.281497,"marketCap":5072187914},{"date":"2021-04-16","current":-3.497732,"twenty":-2.84164,"median":13.078426,"eighty":29.200659,"marketCap":5036734596},{"date":"2021-04-23","current":-3.597855,"twenty":-2.856599,"median":13.071715,"eighty":29.043473,"marketCap":5180911420},{"date":"2021-04-30","current":-3.661868,"twenty":-2.86063,"median":13.065856,"eighty":28.92446,"marketCap":5273090044},{"date":"2021-05-07","current":-5.611001,"twenty":-2.872133,"median":13.00038,"eighty":27.600316,"marketCap":5285562943},{"date":"2021-05-14","current":-5.538196,"twenty":-2.918736,"median":12.98625,"eighty":26.702293,"marketCap":5216980694},{"date":"2021-05-21","current":-5.07124,"twenty":-2.973394,"median":12.984113,"eighty":26.504319,"marketCap":4777108342},{"date":"2021-05-28","current":-5.219361,"twenty":-3.010216,"median":12.953043,"eighty":26.370989,"marketCap":4916637744},{"date":"2021-06-04","current":-5.151577,"twenty":-3.032655,"median":12.935438,"eighty":26.342707,"marketCap":4852785306},{"date":"2021-06-11","current":-5.407649,"twenty":-3.066646,"median":12.921003,"eighty":26.23968,"marketCap":5094005628},{"date":"2021-06-18","current":-5.181703,"twenty":-3.103007,"median":12.910479,"eighty":26.122512,"marketCap":4881164167},{"date":"2021-06-25","current":-5.407649,"twenty":-3.130464,"median":12.883118,"eighty":26.110391,"marketCap":5094005628},{"date":"2021-07-02","current":-5.103877,"twenty":-3.201231,"median":12.837305,"eighty":26.041706,"marketCap":4807852108},{"date":"2021-07-09","current":-4.933162,"twenty":-3.220989,"median":12.808486,"eighty":25.863933,"marketCap":4647038560},{"date":"2021-07-16","current":-4.616837,"twenty":-3.39668,"median":12.795175,"eighty":25.55283,"marketCap":4349060515},{"date":"2021-07-23","current":-4.684621,"twenty":-3.442298,"median":12.778454,"eighty":25.461924,"marketCap":4412912953},{"date":"2021-07-30","current":-4.644453,"twenty":-3.472857,"median":12.762007,"eighty":25.27203,"marketCap":4375074472},{"date":"2021-08-06","current":-5.555659,"twenty":-3.499046,"median":12.754728,"eighty":25.175063,"marketCap":4438971639},{"date":"2021-08-13","current":-5.472783,"twenty":-3.515459,"median":12.739067,"eighty":25.092237,"marketCap":4372753628},{"date":"2021-08-20","current":-5.209355,"twenty":-3.540249,"median":12.712634,"eighty":25.013451,"marketCap":4162274952},{"date":"2021-08-27","current":-5.74509,"twenty":-3.546559,"median":12.705805,"eighty":24.987189,"marketCap":4590327091},{"date":"2021-09-03","current":-5.52902,"twenty":-3.565932,"median":12.702277,"eighty":24.944766,"marketCap":4417687278},{"date":"2021-09-10","current":-5.437265,"twenty":-3.571599,"median":12.695796,"eighty":24.807396,"marketCap":4344374481},{"date":"2021-09-17","current":-5.688853,"twenty":-3.581314,"median":12.675381,"eighty":24.746792,"marketCap":4545393441},{"date":"2021-09-24","current":-5.97004,"twenty":-3.589648,"median":12.636863,"eighty":24.72659,"marketCap":4770061692},{"date":"2021-10-01","current":-5.896043,"twenty":-3.599497,"median":12.622139,"eighty":24.665986,"marketCap":4710938468},{"date":"2021-10-08","current":-5.721411,"twenty":-3.607845,"median":12.595518,"eighty":24.655885,"marketCap":4571407660},{"date":"2021-10-15","current":-5.659254,"twenty":-3.625758,"median":12.578404,"eighty":24.655885,"marketCap":4521744152},{"date":"2021-10-22","current":-5.505341,"twenty":-3.649856,"median":12.569511,"eighty":24.645785,"marketCap":4398767847},{"date":"2021-10-29","current":-5.484622,"twenty":-3.670075,"median":12.545167,"eighty":24.625583,"marketCap":4382213344},{"date":"2021-11-05","current":-8.201051,"twenty":-3.681985,"median":12.518997,"eighty":24.605382,"marketCap":4994440260},{"date":"2021-11-12","current":-7.56811,"twenty":-3.701263,"median":12.505104,"eighty":24.575079,"marketCap":4608979198},{"date":"2021-11-19","current":-7.339009,"twenty":-3.720957,"median":12.481428,"eighty":24.44377,"marketCap":4469456483},{"date":"2021-11-26","current":-6.989532,"twenty":-3.729965,"median":12.465978,"eighty":24.427609,"marketCap":4256625222},{"date":"2021-12-03","current":-6.488616,"twenty":-3.750955,"median":12.411262,"eighty":24.415488,"marketCap":3951567081},{"date":"2021-12-10","current":-7.129323,"twenty":-3.770233,"median":12.390156,"eighty":24.397368,"marketCap":4341757726},{"date":"2021-12-17","current":-6.752665,"twenty":-3.792938,"median":12.369502,"eighty":24.247831,"marketCap":4112372922},{"date":"2021-12-23","current":-7.490449,"twenty":-3.83227,"median":12.348324,"eighty":24.162969,"marketCap":4561683362},{"date":"2021-12-31","current":-7.331243,"twenty":-3.873903,"median":12.336915,"eighty":24.124587,"marketCap":4464726899},{"date":"2022-01-07","current":-7.692369,"twenty":-3.888468,"median":12.314228,"eighty":24.072063,"marketCap":4684652535},{"date":"2022-01-14","current":-7.548695,"twenty":-3.917478,"median":12.283673,"eighty":24.03368,"marketCap":4597155239},{"date":"2022-01-21","current":-7.032246,"twenty":-3.996222,"median":12.241172,"eighty":24.02964,"marketCap":4282637931},{"date":"2022-01-28","current":-6.803145,"twenty":-4.087905,"median":12.214275,"eighty":24.013479,"marketCap":4143115216},{"date":"2022-02-04","current":-7.051662,"twenty":-4.210886,"median":12.177189,"eighty":23.964995,"marketCap":4294461890},{"date":"2022-02-11","current":-7.339009,"twenty":-4.305038,"median":12.115818,"eighty":23.924593,"marketCap":4469456483},{"date":"2022-02-18","current":-9.97933,"twenty":-4.379327,"median":12.077002,"eighty":23.906411,"marketCap":4580512556},{"date":"2022-02-25","current":-9.762948,"twenty":-4.434604,"median":12.034907,"eighty":23.88419,"marketCap":4481193234},{"date":"2022-03-04","current":-9.294121,"twenty":-4.477502,"median":11.989722,"eighty":23.857928,"marketCap":4266001369},{"date":"2022-03-11","current":-9.515655,"twenty":-4.530065,"median":11.874947,"eighty":23.585208,"marketCap":4367685437},{"date":"2022-03-18","current":-9.793479,"twenty":-4.62021,"median":11.802039,"eighty":23.304408,"marketCap":4495206674},{"date":"2022-03-25","current":-9.839796,"twenty":-4.668569,"median":11.613959,"eighty":23.136735,"marketCap":4516466191},{"date":"2022-04-01","current":-10.045649,"twenty":-4.723283,"median":11.244693,"eighty":22.801391,"marketCap":4610952931},{"date":"2022-04-08","current":-8.795089,"twenty":-4.748358,"median":11.177001,"eighty":22.577155,"marketCap":4036945983},{"date":"2022-04-14","current":-9.860381,"twenty":-4.774334,"median":11.132722,"eighty":22.280194,"marketCap":4525914865},{"date":"2022-04-22","current":-9.999332,"twenty":-4.831692,"median":11.002063,"eighty":21.938028,"marketCap":4589693414},{"date":"2022-04-29","current":-10.143429,"twenty":-4.933265,"median":10.846102,"eighty":20.988446,"marketCap":4655834133},{"date":"2022-05-06","current":-13.808923,"twenty":-5.010567,"median":10.72108,"eighty":20.329014,"marketCap":4501708843},{"date":"2022-05-13","current":-13.178967,"twenty":-5.093895,"median":7.386072,"eighty":20.146479,"marketCap":4296343172},{"date":"2022-05-20","current":-11.861786,"twenty":-5.147058,"median":6.828781,"eighty":19.994366,"marketCap":3866942225},{"date":"2022-05-27","current":-13.143174,"twenty":-5.175677,"median":6.45202,"eighty":19.781409,"marketCap":4284674668},{"date":"2022-06-03","current":-13.207601,"twenty":-5.20439,"median":6.373529,"eighty":19.661408,"marketCap":4305677976},{"date":"2022-06-10","current":-12.055068,"twenty":-5.217352,"median":6.1773,"eighty":18.57907,"marketCap":3929952147},{"date":"2022-06-17","current":-10.229627,"twenty":-5.287145,"median":5.839785,"eighty":18.013987,"marketCap":3334858443},{"date":"2022-06-24","current":-10.1652,"twenty":-5.323251,"median":5.651405,"eighty":17.603643,"marketCap":3313855136},{"date":"2022-07-01","current":-9.70705,"twenty":-5.360954,"median":5.101963,"eighty":17.208917,"marketCap":3164498284},{"date":"2022-07-08","current":-9.85738,"twenty":-5.388567,"median":3.861793,"eighty":17.068349,"marketCap":3213506001},{"date":"2022-07-15","current":-9.921808,"twenty":-5.409668,"median":2.45556,"eighty":16.809931,"marketCap":3234509308},{"date":"2022-07-22","current":-10.487336,"twenty":-5.439477,"median":2.417283,"eighty":16.594109,"marketCap":3418871672},{"date":"2022-07-29","current":-11.160244,"twenty":-5.472783,"median":2.404801,"eighty":15.354106,"marketCap":3638239547},{"date":"2022-08-05","current":-56.398031,"twenty":-5.505341,"median":2.387327,"eighty":15.148576,"marketCap":3383881882},{"date":"2022-08-12","current":-60.145409,"twenty":-5.52902,"median":2.299955,"eighty":15.006602,"marketCap":3608724532},{"date":"2022-08-19","current":-55.873399,"twenty":-5.552107,"median":2.257518,"eighty":14.887345,"marketCap":3352403911},{"date":"2022-08-26","current":-53.287708,"twenty":-5.563474,"median":2.212781,"eighty":14.845845,"marketCap":3197262483},{"date":"2022-09-02","current":-52.238442,"twenty":-5.614856,"median":2.207821,"eighty":14.818112,"marketCap":3134306541},{"date":"2022-09-09","current":-54.786659,"twenty":-5.644455,"median":2.197209,"eighty":14.800268,"marketCap":3287199543},{"date":"2022-09-16","current":-52.051073,"twenty":-5.663398,"median":2.187137,"eighty":14.752289,"marketCap":3123064408},{"date":"2022-09-23","current":-44.593792,"twenty":-5.688853,"median":2.168482,"eighty":14.705619,"marketCap":2675627535},{"date":"2022-09-30","current":-42.195471,"twenty":-5.714833,"median":2.125089,"eighty":14.651669,"marketCap":2531728239},{"date":"2022-10-07","current":-43.582,"twenty":-5.729107,"median":2.082185,"eighty":14.616649,"marketCap":2614920019},{"date":"2022-10-14","current":-44.219054,"twenty":-5.777649,"median":2.070313,"eighty":14.587307,"marketCap":2653143270},{"date":"2022-10-21","current":-47.216957,"twenty":-5.925642,"median":2.05882,"eighty":14.530184,"marketCap":2833017390},{"date":"2022-10-28","current":-48.828329,"twenty":-6.246611,"median":2.029326,"eighty":14.486979,"marketCap":2929699729},{"date":"2022-11-04","current":43.862859,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2675634425},{"date":"2022-11-11","current":47.03278,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2868999602},{"date":"2022-11-18","current":45.005505,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2745335826},{"date":"2022-11-25","current":45.742696,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2790304471},{"date":"2022-12-02","current":46.553606,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2839769982},{"date":"2022-12-09","current":45.41096,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2770068581},{"date":"2022-12-16","current":44.342034,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2704864044},{"date":"2022-12-23","current":42.941371,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2619423617},{"date":"2022-12-30","current":43.457404,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2650901669},{"date":"2023-01-06","current":44.010298,"twenty":-6.452657,"median":2.015912,"eighty":14.499284,"marketCap":2684628154},{"date":"2023-01-13","current":46.332449,"twenty":-6.452657,"median":2.015912,"eighty":14.544715,"marketCap":2826279388},{"date":"2023-01-20","current":47.585674,"twenty":-6.452657,"median":2.015912,"eighty":14.591155,"marketCap":2902726086},{"date":"2023-01-27","current":53.188324,"twenty":-6.452657,"median":2.015912,"eighty":14.629303,"marketCap":3244487794},{"date":"2023-02-03","current":54.478409,"twenty":-6.452657,"median":2.015912,"eighty":14.659241,"marketCap":3323182924},{"date":"2023-02-10","current":52.598572,"twenty":-6.452657,"median":2.015912,"eighty":14.710351,"marketCap":3208512877},{"date":"2023-02-17","current":50.681875,"twenty":-6.452657,"median":2.015912,"eighty":14.776825,"marketCap":3091594398},{"date":"2023-02-24","current":19.081678,"twenty":-6.452657,"median":2.015912,"eighty":14.800268,"marketCap":3091231855},{"date":"2023-03-03","current":19.2873,"twenty":-6.452657,"median":2.020509,"eighty":14.820409,"marketCap":3124542543},{"date":"2023-03-10","current":17.080295,"twenty":-6.452657,"median":2.020509,"eighty":14.858004,"marketCap":2767007824},{"date":"2023-03-17","current":15.80726,"twenty":-6.452657,"median":2.020509,"eighty":14.898703,"marketCap":2560776060},{"date":"2023-03-24","current":15.423721,"twenty":-6.452657,"median":2.034301,"eighty":15.020423,"marketCap":2498642845},{"date":"2023-03-31","current":16.930479,"twenty":-6.449731,"median":2.061884,"eighty":15.148576,"marketCap":2742737617},{"date":"2023-04-06","current":16.355172,"twenty":-6.449731,"median":2.08027,"eighty":15.339767,"marketCap":2649537795},{"date":"2023-04-14","current":16.231891,"twenty":-6.452657,"median":2.187137,"eighty":15.656584,"marketCap":2629566405},{"date":"2023-04-21","current":16.1771,"twenty":-6.452657,"median":2.20399,"eighty":16.160663,"marketCap":2620690231},{"date":"2023-04-28","current":15.916842,"twenty":-6.452657,"median":3.861793,"eighty":16.193538,"marketCap":2578528407},{"date":"2023-05-05","current":10.781494,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2716936387},{"date":"2023-05-12","current":11.431806,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2880815089},{"date":"2023-05-19","current":11.705622,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2949816648},{"date":"2023-05-26","current":11.13232,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2805344634},{"date":"2023-06-02","current":11.115206,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2801032037},{"date":"2023-06-09","current":12.184799,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":3070569377},{"date":"2023-06-16","current":11.243558,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2833376518},{"date":"2023-06-23","current":10.71304,"twenty":-6.455582,"median":4.787996,"eighty":16.201756,"marketCap":2699685997},{"date":"2023-06-30","current":10.926958,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2753593465},{"date":"2023-07-07","current":11.226444,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2829063920},{"date":"2023-07-14","current":11.799746,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2973535934},{"date":"2023-07-21","current":11.260671,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2837689115},{"date":"2023-07-28","current":10.76438,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2712623789},{"date":"2023-08-04","current":-57.485197,"twenty":-6.501042,"median":3.861793,"eighty":16.209975,"marketCap":2759289480},{"date":"2023-08-11","current":-60.090736,"twenty":-6.750335,"median":-2.450979,"eighty":16.209975,"marketCap":2884355344},{"date":"2023-08-18","current":-56.854736,"twenty":-6.930509,"median":-2.566048,"eighty":16.209975,"marketCap":2729027307},{"date":"2023-08-25","current":-56.854736,"twenty":-7.00324,"median":-2.678241,"eighty":16.209975,"marketCap":2729027307},{"date":"2023-08-31","current":-58.203069,"twenty":-7.047778,"median":-2.730022,"eighty":16.209975,"marketCap":2793747322},{"date":"2023-09-08","current":-56.225513,"twenty":-7.135536,"median":-2.76742,"eighty":16.220933,"marketCap":2698824633},{"date":"2023-09-13","current":-59.641292,"twenty":-7.238826,"median":-2.81236,"eighty":16.220933,"marketCap":2862782005},{"date":"2023-09-20","current":-56.49518,"twenty":-7.292412,"median":-2.856599,"eighty":16.226412,"marketCap":2711768636},{"date":"2023-09-29","current":-56.270458,"twenty":-7.33179,"median":-2.859478,"eighty":16.256547,"marketCap":2700981967},{"date":"2023-10-06","current":-54.068179,"twenty":-7.350658,"median":-2.872421,"eighty":16.256547,"marketCap":2595272609},{"date":"2023-10-13","current":-54.023235,"twenty":-7.41434,"median":-2.928517,"eighty":16.256547,"marketCap":2593115275},{"date":"2023-10-20","current":-52.944568,"twenty":-7.474917,"median":-3.004751,"eighty":16.256547,"marketCap":2541339263},{"date":"2023-10-23","current":-52.405235,"twenty":-7.491226,"median":-3.007627,"eighty":16.256547,"marketCap":2515451257},{"date":"2023-11-03","current":-48.333767,"twenty":-7.537046,"median":-3.046463,"eighty":16.355172,"marketCap":2706690937},{"date":"2023-11-10","current":-48.821216,"twenty":-7.614707,"median":-3.102759,"eighty":16.355172,"marketCap":2733988086},{"date":"2023-11-17","current":-52.758411,"twenty":-7.692369,"median":-3.147149,"eighty":16.355172,"marketCap":2954470996},{"date":"2023-11-24","current":-54.558271,"twenty":-8.07291,"median":-3.21274,"eighty":16.355172,"marketCap":3055263184},{"date":"2023-12-01","current":-55.60819,"twenty":-8.887723,"median":-3.353198,"eighty":16.355172,"marketCap":3114058626},{"date":"2023-12-08","current":-56.170646,"twenty":-9.20165,"median":-3.416563,"eighty":16.355172,"marketCap":3145556185},{"date":"2023-12-13","current":-57.820518,"twenty":-9.294121,"median":-3.460856,"eighty":16.355172,"marketCap":3237949024},{"date":"2023-12-22","current":-62.432661,"twenty":-9.507389,"median":-3.497732,"eighty":16.36339,"marketCap":3496229004},{"date":"2024-01-05","current":-59.020425,"twenty":-9.574387,"median":-3.519891,"eighty":16.393525,"marketCap":3305143815},{"date":"2024-01-12","current":-60.445315,"twenty":-9.664756,"median":-3.542049,"eighty":16.393525,"marketCap":3384937630},{"date":"2024-01-19","current":-59.99535,"twenty":-9.712777,"median":-3.553469,"eighty":16.401744,"marketCap":3359739584},{"date":"2024-01-26","current":-58.232986,"twenty":-9.763771,"median":-3.571596,"eighty":16.393525,"marketCap":3261047233},{"date":"2024-02-02","current":-66.888565,"twenty":-9.823019,"median":-3.581378,"eighty":16.393525,"marketCap":3210651139},{"date":"2024-02-09","current":-57.220565,"twenty":-9.869644,"median":-3.59147,"eighty":16.393525,"marketCap":3204351628},{"date":"2024-02-16","current":-57.220565,"twenty":-9.956321,"median":-3.604489,"eighty":16.393525,"marketCap":3204351628},{"date":"2024-02-23","current":-60.89528,"twenty":-10.043591,"median":-3.622011,"eighty":16.393525,"marketCap":3410135677},{"date":"2024-03-01","current":35.936019,"twenty":-10.056469,"median":-3.625758,"eighty":16.447807,"marketCap":3485793844},{"date":"2024-03-08","current":37.18843,"twenty":-10.056469,"median":-3.625758,"eighty":16.567212,"marketCap":3607277745},{"date":"2024-03-15","current":36.961243,"twenty":-10.056469,"median":-3.625758,"eighty":16.670221,"marketCap":3585240545},{"date":"2024-03-22","current":38.523902,"twenty":-10.056469,"median":-3.625758,"eighty":16.766106,"marketCap":3736818537},{"date":"2024-03-28","current":38.306866,"twenty":-10.056469,"median":-3.625758,"eighty":16.809931,"marketCap":3715766038},{"date":"2024-04-05","current":37.156575,"twenty":-10.059306,"median":-3.629041,"eighty":16.978896,"marketCap":3604187794},{"date":"2024-04-12","current":37.894498,"twenty":-10.059306,"median":-3.629041,"eighty":17.16064,"marketCap":3675766290},{"date":"2024-04-19","current":35.007918,"twenty":-10.059306,"median":-3.629041,"eighty":17.258612,"marketCap":3395768056},{"date":"2024-04-26","current":35.44199,"twenty":-10.056469,"median":-3.625758,"eighty":17.840762,"marketCap":3437873054},{"date":"2024-05-03","current":36.498796,"twenty":-10.056469,"median":-3.625758,"eighty":18.170174,"marketCap":3357889189},{"date":"2024-05-10","current":36.511207,"twenty":-10.056469,"median":-3.625758,"eighty":18.755351,"marketCap":3359031034},{"date":"2024-05-17","current":37.541304,"twenty":-10.056469,"median":-3.625758,"eighty":19.13678,"marketCap":3453799934},{"date":"2024-05-24","current":36.396752,"twenty":-10.056469,"median":-3.625758,"eighty":19.228198,"marketCap":3348501156},{"date":"2024-05-31","current":35.595565,"twenty":-10.056469,"median":-3.625758,"eighty":19.551549,"marketCap":3274792011},{"date":"2024-06-07","current":34.863052,"twenty":-10.056469,"median":-3.625758,"eighty":19.788169,"marketCap":3207400793},{"date":"2024-06-14","current":34.496795,"twenty":-10.059306,"median":-3.629041,"eighty":19.972394,"marketCap":3173705183},{"date":"2024-06-21","current":33.832955,"twenty":-10.062143,"median":-3.632324,"eighty":20.117746,"marketCap":3112631892},{"date":"2024-06-28","current":34.061866,"twenty":-10.071657,"median":-3.634664,"eighty":20.170141,"marketCap":3133691648},{"date":"2024-07-05","current":33.398026,"twenty":-10.071657,"median":-3.634664,"eighty":20.359437,"marketCap":3072618356},{"date":"2024-07-12","current":32.779968,"twenty":-10.071657,"median":-3.634664,"eighty":20.997672,"marketCap":3015757016},{"date":"2024-07-15","current":33.466699,"twenty":-10.071657,"median":-3.634664,"eighty":21.055774,"marketCap":3078936283},{"date":"2024-08-02","current":10.070358,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":3081529526},{"date":"2024-08-09","current":9.455895,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2893503995},{"date":"2024-08-16","current":9.763127,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2987516760},{"date":"2024-08-23","current":10.179596,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":3114956286},{"date":"2024-08-30","current":10.309316,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":3154650565},{"date":"2024-09-06","current":9.742645,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2981249243},{"date":"2024-09-13","current":9.408104,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2878879787},{"date":"2024-09-20","current":10.718957,"twenty":-10.150883,"median":-3.673418,"eighty":21.101408,"marketCap":3280000919},{"date":"2024-09-27","current":10.084013,"twenty":-10.150883,"median":-3.673418,"eighty":20.560563,"marketCap":3085707871},{"date":"2024-10-04","current":9.585615,"twenty":-10.150883,"median":-3.673418,"eighty":20.205634,"marketCap":2933198274},{"date":"2024-10-11","current":9.756299,"twenty":-10.150883,"median":-3.673418,"eighty":20.146479,"marketCap":2985427588},{"date":"2024-10-18","current":9.626579,"twenty":-10.150883,"median":-3.673418,"eighty":20.146479,"marketCap":2945733309},{"date":"2024-10-25","current":9.462723,"twenty":-10.150883,"median":-3.673418,"eighty":20.138028,"marketCap":2895593168},{"date":"2024-10-31","current":8.714822,"twenty":-10.150883,"median":-3.673418,"eighty":19.647887,"marketCap":2902035670},{"date":"2024-11-08","current":9.117754,"twenty":-10.153746,"median":-3.674208,"eighty":19.166669,"marketCap":3036211945},{"date":"2024-11-15","current":9.111555,"twenty":-10.153746,"median":-3.674208,"eighty":18.78122,"marketCap":3034147899},{"date":"2024-11-22","current":9.099159,"twenty":-10.153746,"median":-3.674208,"eighty":16.930479,"marketCap":3030019806},{"date":"2024-11-29","current":9.638414,"twenty":-10.153746,"median":-3.674208,"eighty":16.766106,"marketCap":3209591825},{"date":"2024-12-06","current":9.756182,"twenty":-10.153746,"median":-3.674208,"eighty":16.574337,"marketCap":3248808703},{"date":"2024-12-13","current":9.53924,"twenty":-10.153746,"median":-3.674208,"eighty":16.377088,"marketCap":3176567086},{"date":"2024-12-20","current":8.968994,"twenty":-10.153746,"median":-3.674208,"eighty":16.1771,"marketCap":2986674836},{"date":"2024-12-27","current":9.334695,"twenty":-10.153746,"median":-3.674208,"eighty":15.960675,"marketCap":3108453562},{"date":"2025-01-03","current":8.541308,"twenty":-10.153746,"median":-3.674208,"eighty":15.74151,"marketCap":2844255649},{"date":"2025-01-10","current":8.398747,"twenty":-10.15661,"median":-3.674999,"eighty":15.187166,"marketCap":2796782587},{"date":"2025-01-17","current":8.429738,"twenty":-10.15661,"median":-3.674999,"eighty":14.123802,"marketCap":2807102818},{"date":"2025-01-24","current":8.541308,"twenty":-10.15661,"median":-3.674999,"eighty":12.229294,"marketCap":2844255649},{"date":"2025-01-31","current":8.355358,"twenty":-10.15661,"median":-3.674999,"eighty":11.774076,"marketCap":2782334264},{"date":"2025-02-07","current":8.175606,"twenty":-10.15661,"median":-3.674999,"eighty":11.669683,"marketCap":2722476924},{"date":"2025-02-14","current":7.915276,"twenty":-10.15661,"median":-3.674999,"eighty":11.541332,"marketCap":2635786984},{"date":"2025-02-21","current":12.449378,"twenty":-10.15661,"median":-3.674999,"eighty":11.52593,"marketCap":2639268117},{"date":"2025-02-28","current":11.712888,"twenty":-10.15661,"median":-3.674999,"eighty":11.52593,"marketCap":2483132177},{"date":"2025-03-07","current":11.32214,"twenty":-10.159473,"median":-3.675279,"eighty":11.440344,"marketCap":2400293756},{"date":"2025-03-14","current":10.388159,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2202289726},{"date":"2025-03-21","current":11.045758,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2341700727},{"date":"2025-03-28","current":10.62642,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2252800958},{"date":"2025-04-04","current":9.263569,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":1963876709},{"date":"2025-04-11","current":8.979147,"twenty":-10.15661,"median":-3.674999,"eighty":11.484858,"marketCap":1903579170},{"date":"2025-04-17","current":9.09341,"twenty":-10.15661,"median":-3.674999,"eighty":11.484858,"marketCap":1927802871},{"date":"2025-04-25","current":9.512373,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2016623108}],"updateTime":1745728928166}}}